## **REMARKS**

Applicants kindly request the amendments to Specification be entered. The first amendment adds the priority claim. No new matter is being added. The other amendments attempt to make the Specification comply with USPTO rules regarding the use of trademarks and the desire to have each table on a single page. The trademarks, Renogen and Peptimune, have been capitalized throughout the Specification. In addition, the generic description of the trademark is present after the first time the trademark is used. No new matter is being added.

Applicants are requesting the cancellation of Claims 1-21 and the addition of new Claims 22-32. Support for Claims 22-32 can be found throughout the Specification. Claims 22-32 attempts to change the originally filed claims into compliance with USPTO practice on claim drafting. No new matter is being added.

Applicant authorizes the Commissioner to charge all fees due to Deposit Account 19-0134. Applicant also requests that all correspondence be directed to the address associated with Customer Number 001095 which is currently as follows:

> Novartis Corporate Intellectual Property One Health Plaza, Building 104 Florham Park East Hanover, NJ 07936-1080

Any questions or issues can be directed to the below signed attorney at this address. Thank you for your assistance with this matter.

Respectfully submitted,

Novartis Corporate Intellectual Property One Health Plaza, Building 104 East Hanover, NJ 07936-1080 (862) 778-7922

Date: January 11, 2005

David L. Marks Attorney for Applicants Reg. No. 37,881